Hepatitis B, C infections, leading causes of death in Ghana - GHS

World Hepatitis Day - WHO urges countries to invest in eliminating...

World Hepatitis Day - WHO urges countries to invest in eliminating...

Hepatitis B (HBV)- It is caused by sexual interaction with a person who has this virus, or with shared needles of blood which are infected with this virus. Hepatitis poses a major global health concern.

Approximately 50 million Indians suffer from chronic hepatitis B infection while 12-18 million others are diagnosed with hepatitis C, these are the latest figures released by the National Center for Biotechnology Information (NCBI), US in the run-up to the World Hepatitis Day observed every year on July 28.

The Ghana Health Service (GHS) has identified the country as having a prevalence of chronic hepatitis B and C virus infections, which are the leading causes of death from infectious diseases globally.

The World Health Organisation (WHO) has set this year's theme as "Invest in eliminating hepatitis" and is urging both policymakers and the public to play their part.

In 2008, the World Hepatitis Alliance in association with patient groups declared May 19th as Hepatitis Day.

- There are several vaccines available for hepatitis A around the world, although none are licensed for children under the age of one.

Each form of hepatitis causes acute or chronic liver disease, but B and C - which are both preventable - are the two most risky. Currently, the majority of experimental HCV vaccines in early clinical trials adopt the mechanism of T cell-mediated immunity.

Hepatitis E: This type of hepatitis is usually mild and short-term and is like hepatitis A is caused by waterborne viruses and travels through the fecal-oral route.

Dr Moutaz Derbala, senior consultant, Gastroenterologist Division, HMC, and Hepatitis Care Programme lead reiterated that Qatar has established a sector-wide response to viral hepatitis epidemics. Treatment, however, remains unaffordable or inaccessible for most in the region.

Officials have also made other considerable efforts in recent years to reduce the transmission rates of Hepatitis C in Luxembourg.

Rastogi's opinion was also sought as the broadsheet, published nearly a week back news on the urgency to take up more liver health and diseases discussions and the inclusion of public health programmes toward this end, quoting Dr. Farhana Bin Lootah of the Imperial College of London Diabetes Centre-Abu Dhabi. According to World Health Organization (WHO), hepatitis is essentially inflammation of the liver. Despite their potent antiviral activity, interferons are typically associated with poor tolerability, harsh side-effects, and long treatment regimens. In Canada and around the globe, people are raising awareness about viral hepatitis. Continued innovations in DAA therapy have resulted in second generation drugs such as Epclusa (sofosbuvir/velpatasvir) that are approved to treat all genetic variations of the hepatitis C virus. Said study was widely praised in Europe as a positive example of detecting and managing hepatitis C and the European Monitoring Center for Drugs and Drug Addiction (EMCDDA) explicitly named Luxembourg as one of the countries that have successfully adopted an innovative approach to hepatitis prevention and testing.